We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of ∆-9-THC and Naloxone in Humans

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01591629
First Posted: May 4, 2012
Last Update Posted: June 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Deepak C. D'Souza, Yale University
April 25, 2012
May 4, 2012
June 23, 2017
July 2011
July 2018   (Final data collection date for primary outcome measure)
Behavioral Measures [ Time Frame: 4 test days ]
Subjective effects and perceptual alterations will be assessed using the Positive and Negative Symptom Subscale (PANNS).
Same as current
Complete list of historical versions of study NCT01591629 on ClinicalTrials.gov Archive Site
  • Visual analog scales [ Time Frame: 4 test days ]
    Will assess subjective effects, perceptual alterations, and cognitive effects.
  • Clinician Administered Dissociative States Scales (CADSS) [ Time Frame: 4 test days ]
    Will measure subjective effects, perceptual alterations, and cognitive effects.
  • Psychotomimetic States Inventory (PSI) [ Time Frame: 4 test days ]
    Will assess subjective effects, perceptual alterations, and cognitive effects.
  • Marijuana Withdrawal Scale [ Time Frame: 4 test days ]
    Will assess subjective effects, perceptual alterations, and cognitive effects.
  • Clinical Opiate Withdrawal Scale [ Time Frame: 4 test days ]
    Will assess subjective effects, perceptual alterations, and cognitive effects.
  • Marijuana Craving Scale [ Time Frame: 4 test days ]
    Will assess subjective effects, perceptual alterations, and cognitive effects.
  • Neuro cognitive battery [ Time Frame: 4 test days ]
    Will assess cognitive effects.
Same as current
Not Provided
Not Provided
 
The Effects of ∆-9-THC and Naloxone in Humans
Assessment of Cannabinoid-opiate Interactions in Humans With a Cannabis Use Disorder and Healthy Subjects
The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Healthy
  • Drug: Naloxone
    Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
  • Drug: Delta-9-THC
    Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
  • Drug: Placebo
    Placebo
  • Placebo Comparator: Placebo and Placebo
    Intervention: Drug: Placebo
  • Experimental: Active Naloxone and Placebo
    Interventions:
    • Drug: Naloxone
    • Drug: Placebo
  • Placebo Comparator: Placebo and Active Delta-9-THC
    Interventions:
    • Drug: Delta-9-THC
    • Drug: Placebo
  • Experimental: Active Naloxone and Active Delta-9-THC
    Interventions:
    • Drug: Naloxone
    • Drug: Delta-9-THC
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
56
July 2018
July 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least one exposure to Cannabis

Exclusion Criteria:

  • Cannabis Naive
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01591629
1108008940
Yes
Not Provided
Not Provided
Deepak C. D'Souza, Yale University
Yale University
Not Provided
Not Provided
Yale University
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP